CN105963633A - Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof - Google Patents
Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof Download PDFInfo
- Publication number
- CN105963633A CN105963633A CN201610303582.XA CN201610303582A CN105963633A CN 105963633 A CN105963633 A CN 105963633A CN 201610303582 A CN201610303582 A CN 201610303582A CN 105963633 A CN105963633 A CN 105963633A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- rhizoma curcumae
- preparation
- curcumae volatile
- emulsifiable paste
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 98
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 201000004681 Psoriasis Diseases 0.000 title abstract description 15
- 235000014375 Curcuma Nutrition 0.000 title abstract 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title abstract 7
- 244000164480 Curcuma aromatica Species 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 63
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 21
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 21
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 21
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 19
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims abstract description 19
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008117 stearic acid Substances 0.000 claims abstract description 19
- GYCKQBWUSACYIF-UHFFFAOYSA-N Ethyl salicylate Chemical compound CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000006071 cream Substances 0.000 claims description 41
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 20
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 20
- 239000003871 white petrolatum Substances 0.000 claims description 20
- 239000003921 oil Substances 0.000 claims description 19
- 230000001185 psoriatic effect Effects 0.000 claims description 19
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 16
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 16
- 239000012071 phase Substances 0.000 claims description 15
- 239000008346 aqueous phase Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- -1 hydroxyl Phenethyl Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 16
- 241000407170 Curcuma Species 0.000 abstract 6
- 229960000541 cetyl alcohol Drugs 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 26
- 241000700199 Cavia porcellus Species 0.000 description 15
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 13
- 229960002475 halometasone Drugs 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 230000001276 controlling effect Effects 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229960002751 imiquimod Drugs 0.000 description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 5
- 206010040882 skin lesion Diseases 0.000 description 5
- 231100000444 skin lesion Toxicity 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960003712 propranolol Drugs 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000035617 depilation Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940127554 medical product Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960004604 propranolol hydrochloride Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 241000963421 Curcuma kwangsiensis Species 0.000 description 1
- 235000003397 Curcuma kwangsiensis Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000028280 polygenic inheritance Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000013309 psoriasis mouse model Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine preparation, and concretely discloses a composition containing volatile oil of curcuma rhizomes for treating psoriasis and a preparation method of an emulsifiable paste preparation thereof. Every one kilogram of the composition containing volatile oil of curcuma rhizomes comprises the following amounts of components: 5-50ml of the volatile oil of curcuma rhizomes, 50-90g of glyceryl monostearate, 100-180g of stearic acid, 50-120g of albolene, 10-40g of cetanol, 0.2-3g of ethyl 2-hydroxybenzoate, 4-12ml of ethyl alcohol, 50-120g of glycerin, 2-16g of sodium dodecyl sulfate, and balance being water. At the same time, the invention also discloses a preparation method of the emulsifiable paste preparation of the composition containing volatile oil of curcuma rhizomes. Active components in the volatile oil of curcuma rhizomes can be used for treating psoriasis directly by means of the emulsifiable paste preparation containing volatile oil of curcuma rhizomes with good treatment effects; a safe and effective external preparation for patients with psoriasis is provided, direct effects of the medicament on affected parts are increased, and the preparation has low cost.
Description
Technical field
The invention belongs to traditional Chinese medicine preparation technical field, treat the combination of psoriatic Rhizoma Curcumae volatile oil particularly to one
Thing and the preparation method of cream preparation thereof.
Background technology
Psoriasis is a kind of common being formed as with keratinocyte hyperplasia, inflammatory cell infiltration and new vessels
The chronic inflammatory skin of Main Tissues pathological change is sick.Unanimously think that psoriasis vulgaris is in polygenic inheritance background at present
Under, the immune disease of T cell unconventionality expression.T cell local activation plays an important role in psoriasis vulgaris, the T of activation
Cell can secrete a series of cytokine, such as interleukin II (IL-2), interleukin-6 (IL-6), interferon-γ
(IFN-γ), tumor necrosis factor-alpha (TNF-α) etc..Treatment at present is many based on local Symptomatic medicine, and conventional has cortex class
Steroid hormone, coal tar, salicylic acid etc., although effectively, but limit clinical practice due to obvious untoward reaction；Card pool three
Alcohol ointment is the internationally recognized medicine treating this disease, but because it is expensive, a lot of patients are unable to be undertaken, thus makes the state of an illness drag
Prolong.
Rhizoma Curcumae is one of psoriatic common drug of Chinese traditional treatment, its acrid in the mouth warm in nature, have circulation of qi promoting removing blood stasis, removing food stagnancy pain relieving it
Effect.Utilizing the effect of the promoting blood circulation to remove obstruction in the collateral of Rhizoma Curcumae, compatibility other drug carries out treating psoriasis clinically, has been achieved for relatively
Good curative effect.There are some researches show that Rhizoma Curcumae can be restrained Keratinocytes in Psoriasis propagation, promote that cutin is formed carefully at present
Born of the same parents' normal differentiation, correct psoriatic parakeratosis of skin.Effective ingredient hence with Rhizoma Curcumae develops new Chinese medicine external system
Agent, can not only provide more safely and effectively medicine for external use for patient, and because its low cost can also alleviate patient burden, it is ensured that suffer from
Person's long-term prescription treatment disease.
The psoriatic clinical practice for the treatment of of existing use Rhizoma Curcumae is many based on oral administration, and oral Chinese medicine onset time is long,
Play a role slow, simultaneously act on whole body, affect the local drug action of Rhizoma Curcumae effective ingredient, limit Rhizoma Curcumae to psoriatic
Therapeutical effect.
Summary of the invention
The main object of the present invention is that the local drug effect treated in the presence of psoriasis technology for existing use Rhizoma Curcumae is made
With limited, patient's compliance is the highest and the above-mentioned deficiency of weak curative effect, it is provided that one treats psoriatic Rhizoma Curcumae volatile oil compositions
And the preparation method of cream preparation, the effective ingredient Rhizoma Curcumae volatile oil of Rhizoma Curcumae can be directly used in psoriasis by this cream preparation
Treatment, produce more preferable therapeutic effect, the most only psoriatic and provide one safely and effectively external preparation, increase medicine
The thing directly effect to affected part, and the advantage with low cost.
In order to realize foregoing invention purpose, the invention provides techniques below scheme:
One treats psoriatic Rhizoma Curcumae volatile oil compositions, it is characterised in that each kilogram of said composition includes following
Each component of amount:
Rhizoma Curcumae volatile oil 5～50ml, glyceryl monostearate 50～90g, stearic acid 100～180g, white vaseline 50～
120g, hexadecanol 10～40g, ethyl hydroxybenzoate 0.2～3g, ethanol 4～12ml, glycerol 50～120g, sodium lauryl sulphate 2～
16g, surplus is water.
Inventor, through numerous studies and screening, has obtained the Rhizoma Curcumae volatile oil compositions ratio of the present invention.Pass through Rhizoma Curcumae
Volatile oil and the precise and appropriate compatibility of pharmaceutic adjuvant, the Rhizoma Curcumae volatile oil compositions treatment psoriasis effect of the present invention is notable.
Preferably, above-mentioned treatment psoriatic Rhizoma Curcumae volatile oil compositions, each kilogram of said composition includes following amounts
Each component:
Rhizoma Curcumae volatile oil 10～40ml, glyceryl monostearate 60～80g, stearic acid 120～160g, white vaseline 60～
110g, hexadecanol 12～30g, ethyl hydroxybenzoate 0.5～2.5g, ethanol 6～10ml, glycerol 60～110g, sodium lauryl sulphate 5
～15g, surplus is water.
By further preferred Rhizoma Curcumae volatile oil composition prescription proportion compatibility, the Rhizoma Curcumae volatile oil compositions of the present invention is made
Using the time long, effectiveness, safety and controllability are optimized further.
It is furthermore preferred that above-mentioned treatment psoriatic Rhizoma Curcumae volatile oil compositions, each kilogram of said composition includes following amounts
Each component:
Rhizoma Curcumae volatile oil 15～35ml, glyceryl monostearate 65～75g, stearic acid 130～150g, white vaseline 70～
100g, hexadecanol 16～25g, ethyl hydroxybenzoate 0.8～1.5g, ethanol 7～9ml, glycerol 70～100g, sodium lauryl sulphate 8
～12g, surplus is water.
Most preferably, above-mentioned treatment psoriatic Rhizoma Curcumae volatile oil compositions, each kilogram of said composition includes following amounts
Each component:
Rhizoma Curcumae volatile oil 20～30ml, glyceryl monostearate 70g, stearic acid 140g, white vaseline 85g, hexadecanol
20g, ethyl hydroxybenzoate 1g, ethanol 8ml, glycerol 85g, sodium lauryl sulphate 10g, surplus is water.
Preferably, above-mentioned treatment psoriatic Rhizoma Curcumae volatile oil compositions, described Rhizoma Curcumae volatile oil is that Rhizoma Curcumae medical material is through water
Steam distillation method is extracted and is obtained.
Preferably, above-mentioned treatment psoriatic Rhizoma Curcumae volatile oil compositions, each adjuvant is pharmaceutical grade.
As second object of the present invention, the present invention provides above-mentioned Rhizoma Curcumae volatile oil compositions to prepare the system of cream preparation
Preparation Method, comprises the following steps:
According to above-mentioned amount, by Rhizoma Curcumae volatile oil, glyceryl monostearate, stearic acid, white vaseline, hexadecanol, oxybenzene second
Ester and ethanol mix homogeneously are heated to 70 DEG C, prepare oil phase；
By soluble in water to glycerol and the sodium lauryl sulphate of above-mentioned amount, it is heated to 70 DEG C, prepares aqueous phase；
Oil phase is slowly added in aqueous phase, stirring, makes cream preparation, stand, cooling.
Preferably, above-mentioned stirring is carried out in homogeneous emulsifying machine.
Compared with prior art, beneficial effects of the present invention:
1, inventor is waved by screening Rhizoma Curcumae volatile oil and the precise and appropriate compatibility of prescription pharmaceutic adjuvant, the Rhizoma Curcumae that the present invention provides
Hair oil cream preparation is significantly increased in character, dispersibility relatively prior art, and further ensures stability and the treatment of medicine
Effect.
2, the technical scheme that the present invention provides is for the deficiency of clinical curing psoriasis means, in conjunction with Rhizoma Curcumae oral medication silver
The effective clinical basis that bits are sick, by extracting and preparing Rhizoma Curcumae volatile oil cream preparation, and by controlling psoriasiform mice
Treatment effect and the mensuration to the cytokine modulating effect in the auricle tissue of psoriasiform Cavia porcellus, determine that psoriasis is controlled by it
Treatment effect and can reduce IF-2 in psoriasiform Cavia porcellus auricle tissue, IL-6, TNF-α exception raise.
3, the present invention solves Rhizoma Curcumae and treats psoriatic confinement problems, changes into traditional oral medication controlling with skin
Treating, the most only psoriatic provides one safely and effectively external preparation, increases the medicine directly effect to affected part, and
Because of its low cost, price is low, provides bigger probability for numerous psoriatics' life-time service.There is no alternative at present
Case.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail.But this should not understood
Scope for the above-mentioned theme of the present invention is only limitted to below example, and all technology realized based on present invention belong to this
The scope of invention.
The Rhizoma Curcumae that the embodiment of the present invention uses, it is zingiberaceous plant Guangxi zedoary Curcuma kwangsiensis
The dry rhizome of S.G.Lee et C.F.Liang, is purchased from Sichuan Neautus Traditional Chinese Medicine Co., Ltd., big by Chengdu Chinese medicine
Learn medicobotany to identify with TCD identification teaching and research room.
The preparation of embodiment 1 Rhizoma Curcumae volatile oil, comprises the following steps:
Take Rhizoma Curcumae medical material 1000g, be crushed to 20～60 mesh, Rhizoma Curcumae powder is added round bottom with water according to the part by weight of 1: 10
In flask, 70 DEG C are soaked 8 hours, are subsequently added stirrer, are placed on heat collecting type constant-temperature heating magnetic stirring apparatus, select volatile oil
Light oil extractor and reflux condensing tube, use steam distillation, extracts volatile oil, and reflux 5h, collects volatile oil.
Embodiment 2 Rhizoma Curcumae volatile oil compositions and the preparation method of cream preparation thereof
Prescription: 1000g cream preparation
Glyceryl monostearate 70g stearic acid 140g white vaseline 85g
Hexadecanol 20g ethyl hydroxybenzoate 1g ethanol 8ml Rhizoma Curcumae volatile oil 40ml
Glycerol 85g sodium lauryl sulphate 10g water 580g
Preparation technology, comprises the following steps:
(1) by Rhizoma Curcumae volatile oil 40ml, glyceryl monostearate 70g, stearic acid 140g, white vaseline 85g, hexadecanol
20g, ethyl hydroxybenzoate 1g and ethanol 8ml, mix homogeneously is heated to 70 DEG C, prepares oil phase.
(2) glycerol 85g, sodium lauryl sulphate 10g being dissolved in 580g water, mix homogeneously is heated to 70 DEG C, prepares water
Phase.
(3) oil phase is slowly added in aqueous phase, is stirred continuously, make cream preparation, stand, cooling.
Embodiment 3 Rhizoma Curcumae volatile oil compositions and the preparation method of cream preparation thereof
Prescription: 1000g cream preparation
Glyceryl monostearate 50g stearic acid 100g white vaseline 50g
Hexadecanol 10g ethyl hydroxybenzoate 0.2g ethanol 4ml Rhizoma Curcumae volatile oil 20ml
Glycerol 50g sodium lauryl sulphate 2g water 728g
Preparation technology, comprises the following steps:
(1) by above-mentioned recipe quantity weigh Rhizoma Curcumae volatile oil, glyceryl monostearate, stearic acid, white vaseline, hexadecanol,
Ethyl hydroxybenzoate and ethanol, mix homogeneously is heated to 70 DEG C, prepares oil phase.
(2) by soluble in water to glycerol and the sodium lauryl sulphate of above-mentioned recipe quantity, mix homogeneously is heated to 70 DEG C, prepares
Aqueous phase.
(3) oil phase is slowly added in aqueous phase, is stirred continuously, make emulsifiable paste, preparation, stand, cooling.
Embodiment 4 Rhizoma Curcumae volatile oil compositions and the preparation method of cream preparation thereof
Prescription: 1000g cream preparation
Glyceryl monostearate 90g stearic acid 180g white vaseline 120g
Hexadecanol 40g ethyl hydroxybenzoate 3g ethanol 12ml Rhizoma Curcumae volatile oil 10ml
Glycerol 120g sodium lauryl sulphate 16g water 369g
Preparation technology, comprises the following steps:
(1) by above-mentioned recipe quantity weigh Rhizoma Curcumae volatile oil, glyceryl monostearate, stearic acid, white vaseline, hexadecanol,
Ethyl hydroxybenzoate and ethanol, mix homogeneously is heated to 70 DEG C, prepares oil phase.
(2) by soluble in water to glycerol, the sodium lauryl sulphate of above-mentioned recipe quantity, mix homogeneously is heated to 70 DEG C, prepares
Aqueous phase.
(3) oil phase is slowly added in aqueous phase, is stirred continuously, make cream preparation, stand, cooling.
Comparative example 1 Rhizoma Curcumae volatile oil compositions and the preparation method of cream preparation thereof
Prescription: 1000g cream preparation
Glyceryl monostearate 20g stearic acid 30g white vaseline 20g
Hexadecanol 2g ethyl hydroxybenzoate 0.05g ethanol 1ml Rhizoma Curcumae volatile oil 5ml
Glycerol 40g sodium lauryl sulphate 1g water surplus
Preparation technology, comprises the following steps:
(1) by above-mentioned recipe quantity weigh Rhizoma Curcumae volatile oil, glyceryl monostearate, stearic acid, white vaseline, hexadecanol,
Ethyl hydroxybenzoate and ethanol, mix homogeneously is heated to 70 DEG C, prepares oil phase.
(2) by soluble in water to glycerol and the sodium lauryl sulphate of above-mentioned recipe quantity, mix homogeneously is heated to 70 DEG C, prepares
Aqueous phase.
(3) oil phase is slowly added in aqueous phase, is stirred continuously, make emulsifiable paste, preparation, stand, cooling.
Comparative example 2 Rhizoma Curcumae volatile oil compositions and the preparation method of cream preparation thereof
Prescription: 1000g cream preparation
Glyceryl monostearate 150g stearic acid 200g white vaseline 120g
Ethyl hydroxybenzoate 3g Rhizoma Curcumae volatile oil 50ml
Glycerol 120g sodium lauryl sulphate 30g water surplus
Preparation technology, comprises the following steps:
(1) Rhizoma Curcumae volatile oil, glyceryl monostearate, stearic acid, white vaseline and oxybenzene second are weighed by above-mentioned recipe quantity
Ester, mix homogeneously is heated to 70 DEG C, prepares oil phase.
(2) by soluble in water to glycerol, the sodium lauryl sulphate of above-mentioned recipe quantity, mix homogeneously is heated to 70 DEG C, prepares
Aqueous phase.
(3) oil phase is slowly added in aqueous phase, is stirred continuously, make cream preparation, stand, cooling.
Reliable and stable in order to verify drug quality of the present invention, that embodiment 2-4 and comparative example 1-2 are produced by applicant Rhizoma Curcumae
Volatile oil cream preparation has carried out the experimental study of storage stability and weatherability, and concrete outcome is as shown in table 1 below: table 1
As it can be seen from table 1 Rhizoma Curcumae volatile oil emulsifiable paste prepared by embodiment of the present invention 2-4 has the weatherability of excellence, with
Time centrifugal test lamination does not occurs yet, there is good storage stability, review comparative example 1, the Rhizoma Curcumae volatile oils of 2 preparations
Its weatherability of emulsifiable paste and storage stability are the most poor, have a strong impact on stablizing of its drug effect.
Test example 1
This test example 1 is the psoriasiform mouse model skin lesion scoring induced imiquimod about Rhizoma Curcumae volatile oil emulsifiable paste
Impact
(1) experiment material
Rhizoma Curcumae volatile oil emulsifiable paste selects the embodiment of the present invention 2, embodiment 3 and the cream preparation of embodiment 4 preparation, three kinds of cowherbs
Every gram of emulsifiable paste suitable Rhizoma Curcumae crude drug 2.0g, 1.0g, 0.5g in art volatile oil emulsifiable paste, dosage is pressed crude drug in whole g/kg and is calculated.
Modeling medicine: 5% imiquimod cream, Sichuan Mingxin Drug Industry Co., Ltd.'s product, lot number 101112.Dosage
Calculate by emulsifiable paste g/kg.
Positive drug: Halometasone Cream, is produced by Hong Kong Australia pharmaceutical factory made in U.S.A.Medical product registration certificate number: HC20100039.
Batch number: 1011554.Specification: 0.5mg/g × 10g/ props up, dosage is pressed halometasone mg/kg and is calculated.
Laboratory animal: Kunming mouse, body weight is 17-19g, and male and female half and half, cleaning grade, by Sichuan Academy of Medical Sciences
Institute of lab animals of People's Hospital, Sichuan Prov. provides, the quality certification number: scxk (river) 2008-24.
(2) experimental technique
Take the mice that body weight is 17-19g, is lost hair or feathers in its back (depilation area be about 2cm × 3cm), by animal with
Machine is divided into negative control group, model control group, Halometasone Cream 0.5mg/kg group, Rhizoma Curcumae volatile oil emulsifiable paste 2.0 crude drug in whole g/kg
Group, Rhizoma Curcumae volatile oil emulsifiable paste 1.0 crude drug in whole g/kg group, Rhizoma Curcumae volatile oil emulsifiable paste 0.5 crude drug in whole g/kg group.Open next day from depilation
Beginning, every morning, remaining each treated animal all smeared 5% imiquimod cream 200mg/kg in depilation district in addition to negative control group,
Negative control group then gives the emulsifiable paste matrix of equivalent, once a day, continuous 14 days.While modeling, every afternoon takes off at it
Hair-fields even spread Halometasone Cream, Rhizoma Curcumae volatile oil each concentration emulsifiable paste or blank emulsifiable paste matrix 10 μ l/10g, once a day, even
Continuous 14 days.Within 7th day and the 14th day, respectively erythema, squama and infiltration thickened degree at mice skin lesion are carried out the most upon administration
Scoring, is then added three's integration and obtains total mark.Its standards of grading are as follows: 0: nothing；1: slight；2: moderate；3: severe；4:
Pole severe.
(3) experimental result
As seen from Table 2, mice after smearing imiquimod the 7th day, there is erythema, squama and thickens etc. similar in its skin
Pigs with Psoriasis, this phenomenon has alleviated for the 14th day after modeling, but its integration summation uses rank test to analyze discovery
Compare with negative control group and still there is statistical significance (P ＜ 0.01).After using variable concentrations Rhizoma Curcumae volatile oil emulsifiable paste, its skin
Skin erythema alleviates, squama rare, and skin is more smooth, and thickening phenomenon is relatively light, and skin lesion symptom improves significantly, and wherein waves with Rhizoma Curcumae
Hair oil emulsifiable paste 2.0 crude drug in whole g/kg group, Rhizoma Curcumae volatile oil emulsifiable paste 1.0 crude drug in whole g/kg group effect are the most notable, with model control group
Relatively there is significant difference (P ＜ 0.01 or P ＜ 0.05)；Rhizoma Curcumae volatile oil emulsifiable paste 0.5 crude drug in whole g/kg group also has skin lesion to alleviate
Trend, but effect more weak, compare no difference of science of statistics (P ＞ 0.05) with model control group.
Test example 2
This test example 2 is, about Rhizoma Curcumae volatile oil emulsifiable paste, the mouse vagina epithelial cell of estrogen-induced is had a karyokinesis
Impact.
(1) experiment material
The Rhizoma Curcumae volatile oil emulsifiable paste selection embodiment of the present invention 2, embodiment 3 and the cream preparation of embodiment 4 preparation, three kinds
Every gram of emulsifiable paste suitable Rhizoma Curcumae crude drug 2.0g, 1.0g, 0.5g in Rhizoma Curcumae volatile oil emulsifiable paste, dosage is pressed crude drug in whole g/kg and is calculated.
Modeling medicine:
Positive drug: Halometasone Cream, is produced by Hong Kong Australia pharmaceutical factory made in U.S.A.Medical product registration certificate number: HC20100039.
Batch number: 1011554.Specification: 0.5mg/g × 10g/ props up, dosage is pressed halometasone mg/kg and is calculated.
Laboratory animal: Kunming mouse, body weight is 18-22g, and male and female half and half, cleaning grade, by Sichuan Academy of Medical Sciences
Institute of lab animals of People's Hospital, Sichuan Prov. provides, the quality certification number: scxk (river) 2008-24.
(2) experimental technique
Take the female mice that body weight is 18-22g, be randomly divided into negative control group, model control group, Halometasone Cream
0.5mg/kg group, Rhizoma Curcumae volatile oil emulsifiable paste 2.0 crude drug in whole g/kg group, Rhizoma Curcumae volatile oil emulsifiable paste 1.0 crude drug in whole g/kg group, Rhizoma Curcumae are waved
Hair oil emulsifiable paste 0.5 crude drug in whole g/kg group.In addition to negative control group lumbar injection 0.10ml/10g normal saline, remaining respectively organizes equal abdomen
Chamber injection estradiol benzoate 1.0mg/kg, once a day, for three days on end (after 3 days, make into inject every other day 1 time, until experiment knot
Bundle), make mouse vagina epithelium be in proliferative state.After modeling, the 4th day starts vaginal injection said medicine or blank emulsion substrate
10 μ l/10g, every day 1 time, continuous 10 days, the 14th day last injected colchicine 2.0mg/ to each group of mouse peritoneal after being administered 1h
Put to death mice after kg, 5h, cut vagina tissue.Fix with 10% formaldehyde, do pathological section, through HE dye after at light microscopic under count
Number.By the mitosis number of 300 basal cells, (mitosis refers to be converted into the karyokinesis numbers that has of 100 basal cells
Number).
(3) experimental result
As seen from Table 3, mouse vagina epithelial cell is after injection estrogen, and its mitotic index dramatically increases, with the moon
Property matched group compares significant difference (P ＜ 0.01)；After using variable concentrations Rhizoma Curcumae volatile oil cream for treating, it has silk
Di substantially reduces, wherein with Rhizoma Curcumae volatile oil emulsifiable paste 2.0 crude drug in whole g/kg group, Rhizoma Curcumae volatile oil emulsifiable paste 1.0 crude drug in whole
G/kg group effect is the most notable, compares with model control group and has significant difference (P ＜ 0.01)；Rhizoma Curcumae volatile oil emulsifiable paste 0.5 is primary
The Long-term change trend of medicine g/kg its mitotic index of group is little, compares no difference of science of statistics (P ＞ 0.05) with model control group.
Test example 3
This test example 3 is about the Rhizoma Curcumae volatile oil emulsifiable paste regulating and controlling effect to psoriasiform animal model cytokine.
(1) experiment material
Rhizoma Curcumae volatile oil emulsifiable paste is selected from the embodiment of the present invention 3, and dosage emulsifiable paste (every gram in Rhizoma Curcumae volatile oil is only selected in this experiment
Emulsifiable paste crude drug 1g Han Rhizoma Curcumae).
The preparation of modeling medicine Propranolol emulsifiable paste: the propranolol hydrochloride tablets bought is ground and makes hydrochloric acid general naphthalene Lip river
That medicated powder, adds emulsifiable paste matrix several times, and stirs, be Propranolol emulsifiable paste (every gram of hydrochloric Propranolol of emulsifiable paste
Sheet 50mg).Propranolol hydrochloride tablets, is produced by Shandong health pharmaceutcal corporation, Ltd.Authentication code: traditional Chinese medicines quasi-word H37020456.
Product batch number: 1003014.Specification: 10mg/ sheet × 100 slice/bottle.
Positive drug: Halometasone Cream, is produced by Hong Kong Australia pharmaceutical factory made in U.S.A.Medical product registration certificate number: HC20100039.
Batch number: 1011554.Specification: 0.5mg/ gram × 10 grams/.
Laboratory animal: albino guinea-pig, male and female half and half, body weight 280-320g, by Sichuan Academy of Medical Sciences Sichuan Province people
Institute of lab animals of people hospital provides, the animal quality certification number: SCXK (river) 2013-15.
Experiment reagent: IL-2, IL-6, IFN-γ, TNF-α ELISA kit, be all purchased from Yaan, Beijing and reach biotechnology
Company limited.
(2) experimental technique
40 Cavia porcelluss are randomly divided into blank group, model control group, Matrix controls group, positive controls, Rhizoma Curcumae volatilization
Oil emulsifiable paste group, often 8 animals of group.Being coated with ears butt skin outside blank group emulsifiable paste matrix, remaining is respectively organized with Propranolol breast
Cream is uniformly outer is coated with ears butt skin, 0.1g/cm2, three times a day, it is coated with 4 weeks continuously.After 4 weeks, except blank group and model comparison
Outside group, each group ears butt skin is outer respectively is coated with emulsifiable paste matrix, Halometasone Cream, Rhizoma Curcumae volatile oil emulsifiable paste, 0.1g/cm2, every day 3
Secondary, continuous 2 weeks.
After medication two weeks, putting to death Cavia porcellus, operation cuts each group of Cavia porcellus right ear specimen, normal saline flushing, removes miscellaneous
Matter, cuts 400mg, puts in 2ml normal saline test tube, homogenate, centrifugal, takes supernatant, and-20 DEG C of Refrigerator stores are to be measured.By examination
The explanation of agent box carries out the mensuration of IL-2, IL-6, IFN-γ, TNF-α.
Experimental data data is usedRepresent, utilize SPSS15.0 statistical package to use One-way ANOVA to enter
Row statistical analysis, P ＜ 0.05, it is believed that difference is statistically significant.
(3) experimental result
Rhizoma Curcumae volatile oil emulsifiable paste is to the regulating and controlling effect of IL-2 in psoriasiform Cavia porcellus auricle tissue:
In model control group Cavia porcellus auricle tissue, IL-2 significantly raises, and compares with blank group, statistically significant (P
＜ 0.01)；Halometasone Cream group IL-2 significantly reduces, and compares with model control group, statistically significant (P ＜ 0.01)；Rhizoma Curcumae
Volatile oil emulsifiable paste group IL-2 significantly reduces, and compares with model control group, statistically significant (P ＜ 0.05).The results detailed in Table 4.
Rhizoma Curcumae volatile oil emulsifiable paste is to the regulating and controlling effect of IL-6 in psoriasiform Cavia porcellus auricle tissue:
In model control group Cavia porcellus auricle tissue, IL-6 significantly raises, and compares with blank group, statistically significant (P
＜ 0.01)；Halometasone Cream group IL-6 significantly reduces, and compares with model control group, statistically significant (P ＜ 0.01)；Rhizoma Curcumae
Volatile oil emulsifiable paste group IL-6 significantly reduces, and compares with model control group, statistically significant (P ＜ 0.05).The results detailed in Table 4.
Rhizoma Curcumae volatile oil emulsifiable paste is to the regulating and controlling effect of IFN-γ in psoriasiform Cavia porcellus auricle tissue:
In model control group Cavia porcellus auricle tissue, IFN-γ significantly raises, and compares with blank group, statistically significant
(P ＜ 0.01)；Halometasone Cream group IFN-γ significantly reduces, and compares with model control group, statistically significant (P ＜ 0.01)；
Rhizoma Curcumae volatile oil emulsifiable paste group IFN-γ, without significantly reducing, compares with model control group, not statistically significant (P ＞ 0.05).Result
Refer to table 4.
Rhizoma Curcumae volatile oil emulsifiable paste is to the regulating and controlling effect of TNF-α in psoriasiform Cavia porcellus auricle tissue:
In model control group Cavia porcellus auricle tissue, TNF-α significantly raises, and compares with blank group, statistically significant (P
＜ 0.01)；Halometasone Cream group, Rhizoma Curcumae volatile oil emulsifiable paste group TNF-α significantly reduce, and compare with model control group, have statistics
Meaning (P ＜ 0.01).The results detailed in Table 4.
The table 2 impact (x ± S) on imiquimod induction psoriasis mouse model skin lesion scoring
Note: compare with model control group,*P ＜ 0.05,**P ＜ 0.01.
Table 3 has the caryocinetic impact of silk (x ± S) to estrogen-induced mouse vagina epithelial cell
Note: compare with model control group,*P ＜ 0.05,**P ＜ 0.01.
Table 4 Rhizoma Curcumae volatile oil emulsifiable paste is to the regulating and controlling effect of cytokine in psoriasiform Cavia porcellus auricle tissue
Note: compare with blank group,*P ＜ 0.05,**P ＜ 0.01；Compare with model control group,ΔP ＜ 0.05,ΔΔP ＜
0.01。
Claims (8)
1. treat psoriatic Rhizoma Curcumae volatile oil compositions for one kind, it is characterised in that each kilogram of said composition includes following amounts
Each component:
Rhizoma Curcumae volatile oil 5～50ml, glyceryl monostearate 50～90g, stearic acid 100～180g, white vaseline 50～120g,
Hexadecanol 10～40g, ethyl hydroxybenzoate 0.2～3g, ethanol 4～12ml, glycerol 50～120g, sodium lauryl sulphate 2～16g,
Surplus is water.
Rhizoma Curcumae volatile oil compositions the most according to claim 1, it is characterised in that each kilogram of said composition includes following
Each component of amount:
Rhizoma Curcumae volatile oil 10～40ml, glyceryl monostearate 60～80g, stearic acid 120～160g, white vaseline 60～
110g, hexadecanol 12～30g, ethyl hydroxybenzoate 0.5～2.5g, ethanol 6～10ml, glycerol 60～110g, sodium lauryl sulphate 5
～15g, surplus is water.
Rhizoma Curcumae volatile oil compositions the most according to claim 2, it is characterised in that each kilogram of said composition includes following
Each component of amount:
Rhizoma Curcumae volatile oil 15～35ml, glyceryl monostearate 65～75g, stearic acid 130～150g, white vaseline 70～
100g, hexadecanol 16～25g, ethyl hydroxybenzoate 0.8～1.5g, ethanol 7～9ml, glycerol 70～100g, sodium lauryl sulphate 8
～12g, surplus is water.
Rhizoma Curcumae volatile oil compositions the most according to claim 3, it is characterised in that each kilogram of said composition includes following
Each component of amount:
Rhizoma Curcumae volatile oil 20～30ml, glyceryl monostearate 70g, stearic acid 140g, white vaseline 85g, hexadecanol 20g, hydroxyl
Phenethyl ester 1g, ethanol 8ml, glycerol 85g, sodium lauryl sulphate 10g, surplus is water.
5. according to the Rhizoma Curcumae volatile oil compositions described in any one of claim 1-4, it is characterised in that described Rhizoma Curcumae volatile oil is
Rhizoma Curcumae medical material obtains through extraction by steam distillation.
Rhizoma Curcumae volatile oil compositions the most according to claim 1, it is characterised in that each adjuvant is pharmaceutical grade.
7. prepare a preparation method for cream preparation treating psoriatic Rhizoma Curcumae volatile oil compositions described in claim 1,
It is characterized in that, comprise the following steps:
According to described usage ratio, by Rhizoma Curcumae volatile oil, glyceryl monostearate, stearic acid, white vaseline, hexadecanol, oxybenzene
Ethyl ester and ethanol mix homogeneously are heated to 70 DEG C, prepare oil phase；
By soluble in water to glycerol and the sodium lauryl sulphate of described usage ratio, it is heated to 70 DEG C, prepares aqueous phase；Oil phase is delayed
In slow addition aqueous phase, stirring, make cream preparation, stand, cooling.
Preparation method the most according to claim 7, it is characterised in that described stirring is carried out in homogeneous emulsifying machine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610303582.XA CN105963633A (en) | 2016-05-10 | 2016-05-10 | Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610303582.XA CN105963633A (en) | 2016-05-10 | 2016-05-10 | Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963633A true CN105963633A (en) | 2016-09-28 |
Family
ID=56991557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610303582.XA Pending CN105963633A (en) | 2016-05-10 | 2016-05-10 | Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963633A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113318069A (en) * | 2021-05-18 | 2021-08-31 | 南方医科大学皮肤病医院 | Anti-inflammatory topical cream for treating psoriasis and preparation method thereof |
| CN116098978A (en) * | 2022-12-24 | 2023-05-12 | 北京斯利安药业有限公司 | Chinese medicinal cream for treating psoriasis and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857676A (en) * | 2006-03-14 | 2006-11-08 | 温州医学院 | Zedoary oil microcapsule preparation and its preparing process |
| CN100522137C (en) * | 2007-02-16 | 2009-08-05 | 遵义医学院附属医院 | Cream for treating psoriasis and its preparing process |
| CN103007199A (en) * | 2012-12-28 | 2013-04-03 | 浙江康恩贝制药股份有限公司 | Preparation method of zedoary volatile oil clathrate |
| CN103127442A (en) * | 2011-11-22 | 2013-06-05 | 青岛康地恩药业股份有限公司 | Preparation process of zedoary oil submicron emulsion |
| CN104173907A (en) * | 2013-05-20 | 2014-12-03 | 广州中医药大学第二附属医院 | Application of zedoary turmeric oil in preparation of psoriasis treatment medicines |
| CN104906501A (en) * | 2014-03-14 | 2015-09-16 | 广州中医药大学第二附属医院 | Chinese herbal component composition for treatment of psoriasis |
| CN105079720A (en) * | 2015-09-22 | 2015-11-25 | 四川省人民医院 | Curcumenol extract emulsifiable paste and application of curcumenol extract emulsifiable paste in medicine for treating psoriasis |
-
2016
- 2016-05-10 CN CN201610303582.XA patent/CN105963633A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857676A (en) * | 2006-03-14 | 2006-11-08 | 温州医学院 | Zedoary oil microcapsule preparation and its preparing process |
| CN100522137C (en) * | 2007-02-16 | 2009-08-05 | 遵义医学院附属医院 | Cream for treating psoriasis and its preparing process |
| CN103127442A (en) * | 2011-11-22 | 2013-06-05 | 青岛康地恩药业股份有限公司 | Preparation process of zedoary oil submicron emulsion |
| CN103007199A (en) * | 2012-12-28 | 2013-04-03 | 浙江康恩贝制药股份有限公司 | Preparation method of zedoary volatile oil clathrate |
| CN104173907A (en) * | 2013-05-20 | 2014-12-03 | 广州中医药大学第二附属医院 | Application of zedoary turmeric oil in preparation of psoriasis treatment medicines |
| CN104906501A (en) * | 2014-03-14 | 2015-09-16 | 广州中医药大学第二附属医院 | Chinese herbal component composition for treatment of psoriasis |
| CN105079720A (en) * | 2015-09-22 | 2015-11-25 | 四川省人民医院 | Curcumenol extract emulsifiable paste and application of curcumenol extract emulsifiable paste in medicine for treating psoriasis |
Non-Patent Citations (3)
| Title |
|---|
| 宋智琦等: "莪术油霜剂外用治疗银屑病的药效学及作用机制研究", 《中国皮肤性病学杂》 * |
| 田应彪: "复方莪术油乳膏治疗银屑病样动物模型作用研究", 《中药药理与临床》 * |
| 陈璐等: "莪术挥发油乳膏对银屑病样豚鼠细胞因子的影响", 《中国药理学会第三届治疗药物监测学术年会》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113318069A (en) * | 2021-05-18 | 2021-08-31 | 南方医科大学皮肤病医院 | Anti-inflammatory topical cream for treating psoriasis and preparation method thereof |
| CN116098978A (en) * | 2022-12-24 | 2023-05-12 | 北京斯利安药业有限公司 | Chinese medicinal cream for treating psoriasis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181623B (en) | Method for preparing alcohol extraction of white vein ointment | |
| CN109745361A (en) | It is a kind of to alleviate senile skin itch and the compound skin cream and its preparation method and application with moisturizing effect | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN101292997B (en) | Pharmaceutical composition for treating empyrosis or gastric ulcer, and preparation method thereof | |
| CN105963633A (en) | Composition containing volatile oil of curcuma rhizomes for treating psoriasis and preparation method of emulsifiable paste preparation thereof | |
| CN105079720B (en) | A kind of curcuma zedoary alcohol extract emulsifiable paste and its purposes in treatment psoriasis | |
| CN101953889B (en) | Compound ceftiofur suspension emulsion injection and preparation method thereof | |
| CN112972484A (en) | Application of trilobatin in preparation of medicine for promoting skin wound healing | |
| CN111388467A (en) | New application of indigo | |
| CN106361830A (en) | Rhubarb powder and preparation method thereof | |
| CN105148230B (en) | Medicine for treating cancer pain and preparation method thereof | |
| CN105287742A (en) | Ointment capable of controlling mosquito bite and preparation method thereof | |
| CN104606628A (en) | Face-nourishing, beautifying and chloasma-removing traditional Chinese medicine composition | |
| CN104958385B (en) | A kind of Chinese medicine composition, its preparation method and Chinese medicine preparation | |
| CN109512992A (en) | A kind of Chinese medicine composition treatment anus is red and swollen and the drug of hemorrhoid in application | |
| CN104873733B (en) | A kind of functional pharmaceutical chemistry inhibiting female soft-shelled turtle gonad development and preparation method thereof and feeding method | |
| CN101020036A (en) | Externally applied prepn for treating trauma and its prepn process | |
| CN101564433B (en) | Chinese medicinal composition for treating rheumatic diseases, and preparation method thereof | |
| CN105998134A (en) | Chinese herbal ointment for treating and repairing skin scalds | |
| CN100408085C (en) | Snow lotus preparation for treating prostate disease | |
| CN103330919A (en) | Traditional Chinese medicine compound cream for curing hyperplasia of mammary glands and preparation method thereof | |
| JPH06107553A (en) | Composition having analgesic function | |
| CN102614341B (en) | Chinese medicinal composition for promoting fracture healing | |
| CN101024029A (en) | Medicine for treating bony arthritis, rheumatism arthritis | |
| CN104474469A (en) | Method for preparing electric injury paste preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |